In this video, Shahzad Raza, MD, discusses teclistamab as a potential treatment for patients with relapsed or refractory systemic light chain amyloidosis.“Teclistamab has already been approved in ...

In this video, Shahzad Raza, MD, discusses safety and efficacy data from Nexicart-2, which studied the use of chimeric antigen receptor T-cell therapy in relapsed or refractory light chain amyloidosis ...

Learn how ATTR-CM is treated with medications that slow down the condition's progression and other therapies that reduce symptoms and improve the quality of life.

The skin often reflects heart health. Harvard doctors highlight skin signs that may indicate cardiovascular issues. These ...

Discover the current challenges in diagnosing multiple myeloma and how advances in diagnostic technologies could help ...

Landmark approval is based on results from the Phase 3 AQUILA study, showing fixed-duration treatment with daratumumab significantly reduced the risk of progression to active multiple myeloma or death ...